Ascendis Pharma A/S
243.37USD
+0.3800 (+0.16%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ASND.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | €0.94▼ | €1.32 | 0 | 1 |
| Next quarter | €1.15▼ | €1.59 | 0 | 1 |
| Current year | €11.32▼ | €11.73 | 1 | 1 |
| Next year | €7.98▼ | €9.29 | 0 | 2 |
Beat in 2 of the last 2
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | €0.77 | €0.9 | +0.13 (+17.4%) |
| 2026-03-31 | -€0.08 | €0.27 | +0.35 (+429.3%) |
233 ratings from 25 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Reiterated | Overweight | $300 | Sep 25, 2026 |
| Raymond James | Downgraded from Strong Buy | Outperform | $287 | Sep 15, 2026 |
| Oppenheimer | Maintained | Outperform | $304 $312 | Sep 2, 2026 |
| Morgan Stanley | Maintained | Overweight | $275 $273 | Sep 1, 2026 |
| Wedbush | Reiterated | Outperform | $327 | Sep 1, 2026 |
| B of A Securities | Maintained | Buy | $306 $304 | Aug 31, 2026 |
| Jefferies | Maintained | Buy | $333 $330 | Aug 31, 2026 |
| Stifel | Maintained | Buy | $328 $326 | Aug 31, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $345 $344 | Aug 31, 2026 |
| HC Wainwright & Co. | Initiated | Buy | $345 | Aug 27, 2026 |
| BMO Capital | Initiated | Outperform | $319 | Aug 19, 2026 |
| TD Cowen | Maintained | Buy | $325 $341 | Aug 14, 2026 |
| RBC Capital | Maintained | Outperform | $280 $290 | Aug 14, 2026 |
| Barclays | Maintained | Overweight | $345 $329 | Aug 14, 2026 |
| Morgan Stanley | Maintained | Overweight | $256 $275 | Jul 23, 2026 |
| RBC Capital | Maintained | Outperform | $275 $280 | Jul 7, 2026 |
| Citigroup | Initiated | Buy | $355 | May 19, 2026 |
| Evercore ISI Group | Maintained | Outperform | $324 $329 | May 15, 2026 |
| Barclays | Maintained | Overweight | $342 $345 | May 11, 2026 |
| Wells Fargo | Maintained | Overweight | $330 $326 | May 8, 2026 |
| B of A Securities | Maintained | Buy | $262 $292 | Apr 16, 2026 |
| Wedbush | Reiterated | Outperform | $273 | Apr 9, 2026 |
| RBC Capital | Maintained | Outperform | $250 $275 | Mar 3, 2026 |
| Oppenheimer | Maintained | Outperform | $246 $262 | Feb 12, 2026 |
| Wedbush | Maintained | Outperform | $240 $273 | Feb 12, 2026 |
6 filings from 3 insiders · 6 buy / 3 sell over 6m
Officers and directors of ASND, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bodenhoff MadsOfficer, SVP & PAO | ExerciseWarrants | 3.0k | — | — | Sep 8, 2026 |
| Bodenhoff MadsOfficer, SVP & PAO | Sell | 3.0k | $270.19 | $811k | Sep 8, 2026 |
| Bodenhoff MadsOfficer, SVP & PAO | Exercise | 3.0k | $110.00 | $330k | Sep 8, 2026 |
| HOLTUG LARSDirector | Sell | 236 | $264.13 | $62k | Sep 2, 2026 |
| BIENAIME JEAN JACQUESDirector | GrantWarrants | 9.2k | — | — | Apr 14, 2026 |
| BIENAIME JEAN JACQUESDirector | OtherWarrants | 9.2k | — | — | Apr 14, 2026 |
No analyst notes on ASND yet.
Analyst Ratings
21 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 5 | 16 | 0 | 0 | 0 | Buy1.76 |
| 1 mo ago | 5 | 15 | 0 | 0 | 0 | Buy1.75 |
| 2 mo ago | 4 | 16 | 0 | 0 | 0 | Buy1.80 |
| 3 mo ago | 4 | 14 | 0 | 0 | 0 | Buy1.78 |
Members whose judged calls on ASND have played out most reliably.
No settled calls on ASND yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice